English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Monday, May 8, 2023
Eisai Enters Into Joint Development Agreement with Blissbio for Antibody Drug Conjugate BB-1701 with Option Rights for Strategic Collaboration
エーザイ、抗体薬物複合体BB-1701について、BlissBioと戦略的提携に向けたオプション権を有する共同開発契約を締結
Thursday, April 6, 2023
Eisai Completes a Major Renovation of Tsukuba Research Laboratories
エーザイ、筑波研究所の大規模改修工事が竣工
Tuesday, April 4, 2023
Eisai Publishes Long-Term Health Outcomes Using Simulation Model of Lecanemab Using Phase 3 Clarity Ad Data in Peer-Reviewed Neurology and Therapy Journal
エーザイ、臨床第III相Clarity AD試験データを用いた「レカネマブ」の長期的健康アウトカムについて、シミュレーションを用いた評価結果が査読学術専門誌Neurology and Therapy誌に掲載
Monday, April 3, 2023
Eisai Enters Into Agreement With National Cancer Center to Collaborate on Investigator-Initiated Clinical Research for Anticancer Agent Tazemetostat Based on "Patient-Proposed Healthcare Services" System
エーザイ、抗がん剤タゼメトスタットについて、「患者申出療養」制度に基づく医師主導臨床研究への協力に関する契約を国立がん研究センターと締結
Friday, March 31, 2023
Eisai Presented New Analyses of Aria and QOL on Lecanemab in Clarity AD at the AD/PD 2023 Annual Meeting
Eisai: Additional Detailed Analyses from Phase 2 Study 201 of Lecanemab Published as Three Papers in Peer-Reviewed Journals

Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575